-Bloomberg
This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage
Short-acting psychedelics biotech company Small Pharma Inc.
FTC’s Khan Calls For Blocking More M&A As Lockheed Deal Looms
-Bloomberg
Related Posts
Partner Communications Clocks 2% Revenue Growth In Q2
Partner Communications Company Ltd (NASDAQ:PTNR) reported second-quarter FY22 revenue growth of 2% year-on-year to $245 million. Service revenue rose 9% Y/Y…
Speaker Nancy Pelosi Says Democrats Close To Agreement On Topline For Biden Bill
Dear Colleague on Path to Passing the Build Back Better Act and the Bipartisan Infrastructure Framework Into Law